WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 5128

Legislative bill overview

HB 5128 establishes regulatory requirements for direct-to-consumer (DTC) genetic testing companies operating in Connecticut. The bill likely defines standards for informed consent, data privacy, result accuracy, and company licensing or registration to protect consumers purchasing genetic tests without healthcare provider intermediation.

Why is this important

DTC genetic testing is a rapidly growing industry where consumers order ancestry, health risk, or pharmacogenomic tests directly online. Without state oversight, consumers may face misleading health claims, inadequate counseling about results, misuse of genetic data, or breach of privacy—particularly concerning given the sensitive nature of genetic information and its potential use by insurers or employers.

Potential points of contention

  • Healthcare provider involvement: Debate over whether genetic results should require physician interpretation or if consumers can receive results directly, balancing consumer autonomy against medical necessity
  • Data security and ownership: Tension between protecting genetic data from law enforcement access and third-party sales versus allowing legitimate research use
  • Testing accuracy standards: Disagreement on which tests should be permitted or required to meet clinical validation standards, potentially limiting consumer choice or enabling unproven tests

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.